Clinical trials: Refractory Pain
Coronary Artery Disease, Ischemia
Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)
The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options.
- Conditions
- Coronary Artery Disease, Ischemia, Angina Refractory, Cardiovascular Diseases
- Trial name
- EXACT (NCT04125732)
- Testing
- AdVEGFXC1
- Where
- 16 sites in United States
- Volunteers
- 41 people
- Sponsor
- XyloCor Therapeutics, Inc.
Intractable Pain, Neoplasms
NP2 Enkephalin For Treatment of Intractable Cancer Pain
The purpose of this study is to examine the impact of intradermal delivery of NP2 on pain scores and pain medication usage in subjects with intractable pain due to malignant disease.
- Trial name
- NCT01291901
- Testing
- NP2
- Where
- 18 sites in United States
- Volunteers
- 33 people
- Sponsor
- Diamyd Inc
Chronic Intractable Pain
A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain
The purpose of this study is to determine the safety and minimum effective dose of intraspinal gabapentin when delivered through an implanted drug infusion system.
- Trial name
- NCT00414466
- Testing
- Intraspinal Gabapentin
- Where
- 14 sites in United States
- Volunteers
- 254 people
- Sponsor
- MedtronicNeuro
Chronic Pain, Cancer Pain
Prometra Post-Approval Study
The Prometra Pump is approved by the FDA for use in the United States. The purpose of this study is to collect long-term safety data on the Prometra Pump.
- Conditions
- Chronic Pain, Cancer Pain, Intractable Pain, Back Pain
- Trial name
- NCT01854229
- Testing
- Prometra Programmable Intrathecal Infusion Pump
- Where
- 26 sites in United States
- Volunteers
- 400 people
- Sponsor
- Flowonix Medical
Intractable Cancer Pain
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
The study is a multicenter, open-label Phase 1b single dose escalation safety study for adult subjects with intractable pain associated with cancer in any area below the mid-thoracic level who meet all other eligibility criteria.
- Trial name
- NCT03226574
- Testing
- Resiniferatoxin
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Sorrento Therapeutics, Inc.
Chronic Pain
A Post Market Evaluation of Chronic intractaBle paIN and the Efficacy of drG stimulatiOn in the Nordic Region
11-SMI-2013 is a post market, observational, questionnaire based study to assess the effectiveness of the commercially available Axium neurostimulator in the management of intractable, chronic pain
- Trial name
- BINGO (NCT02346643)
- Testing
- Implantation with the commercially available Axium Neurostimulator
- Where
- 2 sites in Sweden
- Volunteers
- 41 people
- Sponsor
- Abbott Medical Devices
Pain, Intractable, Pain Cancer
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
This is a Phase 3 study to assess the safety and efficacy of a single epidural administration of Resiniferatoxin versus standard of care for the treatment of intractable pain associated with cancer.
- Trial name
- NCT04572776
- Testing
- Resiniferatoxin, Standard of Care
- Sponsor
- Sorrento Therapeutics, Inc.
Chronic Pain, Intractable Pain
Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator
The TRIUMPH study is a post-market, international, multicenter, interventional, prospective, single-arm study intended to evaluate the sustainability of pain control and psychosocial and functional responses utilizing a…
- Trial name
- TRIUMPH (NCT03082261)
- Testing
- Prodigy, Prodigy MRI or Proclaim Elite IPG
- Where
- 22 sites in United States, Canada and 5 more
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Abbott Medical Devices
Osteoarthritis of the Knee
Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis
The study will identify the efficacy of Apitox, purified honeybee toxin, in 330 patients with diagnosed osteoarthritis of the knee.
- Trial name
- NCT01112722
- Testing
- Apitox, purified honeybee toxin, lyophilized in saline, histamine
- Where
- 15 sites in United States
- Volunteers
- 363 people
- Sponsor
- Apimeds, Inc.
Pain, Chronic Pain
Efficacy and Safety of Spinal Cord Stimulation in Patients With Chronic Intractable Pain
The purpose of this study is to evaluate the efficacy and safety of spinal cord stimulation (SCS) using the PINS spinal cord stimulator device for chronic and intractable pain.
- Conditions
- Pain, Chronic Pain, Back Pain, Spinal Cord Stimulation
- Trial name
- NCT03858790
- Testing
- PINS Spinal Cord Stimulator
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Lumbar Discogenic Pain (Disorder)
Ethanol Gel Versus Steroid in Refractory Lumbar Discogenic Pain
DISCOGEL® is on the market since 2007. About 20,000 kits were sold to date (October 2017). The device re-obtained its CE mark in 2017. A clinical evaluation was performed by bibliographic route in 2016.
- Trial name
- IDIS (NCT03415828)
- Testing
- Ethanol gel, Prednisolone acetate
- Where
- 5 sites in France
- Volunteers
- 230 people
- Sponsor
- Gelscom SAS
Refractory Angina Pectoris
Extracorporeal Shockwave Therapy for the Treatment of Refractory Chronic Angina Pectoris
Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones. The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with…
- Trial name
- NCT01567644
- Testing
- Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Medispec
Refractory Angina
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence…
- Trial name
- COSIRA-II (NCT05102019)
- Testing
- Arm 1: treatment with Shockwave Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry
- Where
- 97 sites in United States, Canada and 1 more
- Volunteers
- 380 people
- Sponsor
- Shockwave Medical, Inc.
Refractory Angina
Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina
Therapeutic neovascularization is an innovative strategy for cardiac tissue recovery due to chronic, intense ischemia. Thus stem cell therapy has become a promising procedure for the large number of patients with refractory…
- Trial name
- ReACT (NCT01966042)
- Testing
- Local sedation, Bone Marrow Aspiration, Minithoracotomy
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- CellPraxis Bioengenharia Ltda.
Pain, Intractable
Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics
The purpose of this study is to verify the effectiveness, and safety in Japanese patients with chronic intractable pain after 4-week medication of fentanyl transdermal matrix patches containing either 12.5 mcg/hr, 25 mcg/hr, 50…
- Trial name
- NCT00216684
- Testing
- fentanyl
- Volunteers
- 139 people
- Sponsor
- Janssen Pharmaceutical K.K.
Chronic, Intractable Back Pain and/or Leg Pain
Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain
This is a single-center, prospective, non-randomized exploratory study in subjects with chronic, intractable back pain and/or leg pain per the center's routine practice.
- Trial name
- MED (NCT06897280)
- Testing
- SCS Device Program Setting
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Nevro Corp
Intractable Pain, Back Pain
Prometra's Utilization in Mitigating Pain II
Intrathecal infusion pumps are increasingly used to deliver analgesics for chronic intractable pain. The PUMP II trial is designed to evaluate the ongoing safety and efficacy of the new Prometra® Programmable Pump System for…
- Conditions
- Intractable Pain, Back Pain, Leg Pain, Arm Pain
- Trial name
- (PUMP 2) (NCT00866164)
- Testing
- Prometra Programmable Pump
- Sponsor
- Flowonix Medical
Chronic Pain, Intractable Pain
Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial
The purpose of the study is to assess the feasibility of using information extracted from physiologic signals to automatically adjust stimulation in patients undergoing Spinal Cord Stimulation (SCS).
- Conditions
- Chronic Pain, Intractable Pain, Low Back Pain, Pain, Neuropathic
- Trial name
- AIM (NCT04909593)
- Testing
- Spinal Cord Stimulation
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Boston Scientific Corporation
Back Pain
Comparison of HF10 Therapy Combined With CMM to CMM Alone in the Treatment of Non-Surgical Refractory Back Pain
This study is being conducted to document the safety, clinical effectiveness and cost-effectiveness of high-frequency SCS at 10 kHz (HF10™ Therapy) delivered through the Senza system in subjects with chronic refractory back pain…
- Trial name
- NSRBP (NCT03680846)
- Testing
- HF10 Therapy, CMM
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- Nevro Corp
Chronic Pain
High Rate Spinal Cord Stimulation (SCS) for Chronic Pain
To determine the effects of varying spinal cord stimulation programming parameters, including stimulation rate, on pain intensity.
- Trial name
- NCT01624740
- Testing
- Low Rate Stimulation, High Rate Stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation